Author:
Zhang Ming-Wu,Zhou Lin,Zhang Yu,Chen Bin,Peng Ying,Wang Fei,Liu Zheng-Wei,Wang Xiao-Meng,Chen Song-Hua
Abstract
Abstract
Background
The aim of this study was to assess the treatment outcomes of multidrug and extensively drug-resistant tuberculosis (M/XDR-TB) in Zhejiang, China and to evaluate possible risk factors associated with poor outcomes of M/XDR-TB.
Methods
Two-hundred-and-sixty-two patients having M/XDR-TB who received the diagnosis and treatment at nine referral hospitals from 1 January 2016 to 31 December 2016 in Zhejiang, China were included. All patients received second-line regimens recommended by WHO under the DOTS-Plus strategy.
Results
Among the 262 patients, the treatment success rate was 55.34% (n = 145) with 53.44% (n = 140) cured and 1.91% (n = 5) who completed treatment, 62 (23.66%) failed, 27 (10.31%) died, 16 (6.11%) defaulted and 12 (4.58%) transferred out. Forty (64.52%) of the 62 M/XDR-TB patients who failed treatment were due to adverse effects in the first 10 months of treatment. Eighteen patients (6.37%) had XDR-TB. Treatment failure was significantly higher among patients with XDR-TB at 50% than that among patients with non-XDR-TB at 21.72% (P = 0.006). Failure outcomes were associated with a baseline weight less than 50 kg (OR, 8.668; 95% CI 1.679–44.756; P = 0.010), age older than 60 years (OR, 9.053; 95% CI 1.606–51.027; P = 0.013), hemoptysis (OR, 8.928; 95% CI 1.048–76.923; P = 0.045), presence of cavitary diseases (OR, 10.204; 95% CI 2.032–52.631; P = 0.005), or treatment irregularity (OR, 47.619; 95% CI 5.025–500; P = 0.001).
Conclusion
Treatment outcomes for M/XDR-TB under the DOTS-Plus strategy in Zhejiang, China were favorable but still not ideal. Low body weight (< 50 kg), old age (> 60 years), severe symptoms of TB including cavitary disease, hemoptysis and irregular treatment were independent prognostic factors for failure outcomes in patients with M/XDR-TB.
Funder
Health Commission of Zhejiang Province
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. WHO. Global tuberculosis report 2020. WHO/HTM/TB/202011 2020. (https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf)
2. Compendium of TB/COVID-19 studies. Geneva: World Health Organization; 2020 (https://www.who.int/ teams/global-tuberculosis-programme/covid-19/compendium, accessed 29 July 2020).
3. Digital health for the End TB Strategy: an agenda for action (WHO/HTM/TB/2015.21). Geneva: WHO; 2015 (https://www.who.int/tb/publications/digitalhealth-TB-agenda/en/, accessed 29 July 2020).
4. Pang Y, Lu J, Huo F, Ma Y, Zhao L, Li Y, Liang Q, Chu N, Gao M, Huang H. Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: A five-year review. J Infect. 2017;75:433–40.
5. Wu B, Zhang L, Liu Z, He H, Pan A, Wang F, Zhang M, Chen B, Lu Z, Chen S, Wang X. Drug-resistant tuberculosis in Zhejiang Province, China: an updated analysis of time trends, 1999–2013. Glob Health Action. 2017;10:1293925.